vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and TOOTSIE ROLL INDUSTRIES INC (TR). Click either name above to swap in a different company.
TOOTSIE ROLL INDUSTRIES INC is the larger business by last-quarter revenue ($196.3M vs $168.4M, roughly 1.2× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 1.5%). Over the past eight quarters, TOOTSIE ROLL INDUSTRIES INC's revenue compounded faster (13.2% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Tootsie Roll Industries is an American manufacturer of confectionery based in Chicago, Illinois. Its best-known products include the namesake Tootsie Rolls and Tootsie Pops. Tootsie Roll Industries currently markets its brands internationally in Canada, Mexico, and over 75 other countries.
ESPR vs TR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $196.3M |
| Net Profit | — | $28.8M |
| Gross Margin | — | 35.7% |
| Operating Margin | 50.6% | 17.0% |
| Net Margin | — | 14.7% |
| Revenue YoY | 143.7% | 1.5% |
| Net Profit YoY | — | 27.9% |
| EPS (diluted) | $0.32 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $196.3M | ||
| Q3 25 | $87.3M | $232.7M | ||
| Q2 25 | $82.4M | $155.1M | ||
| Q1 25 | $65.0M | $148.5M | ||
| Q4 24 | $69.1M | $193.4M | ||
| Q3 24 | $51.6M | $225.9M | ||
| Q2 24 | $73.8M | $150.7M | ||
| Q1 24 | $137.7M | $153.2M |
| Q4 25 | — | $28.8M | ||
| Q3 25 | $-31.3M | $35.7M | ||
| Q2 25 | $-12.7M | $17.5M | ||
| Q1 25 | $-40.5M | $18.1M | ||
| Q4 24 | — | $22.5M | ||
| Q3 24 | $-29.5M | $32.8M | ||
| Q2 24 | $-61.9M | $15.6M | ||
| Q1 24 | $61.0M | $15.8M |
| Q4 25 | — | 35.7% | ||
| Q3 25 | — | 34.1% | ||
| Q2 25 | — | 36.4% | ||
| Q1 25 | — | 35.3% | ||
| Q4 24 | — | 39.1% | ||
| Q3 24 | — | 34.1% | ||
| Q2 24 | — | 33.5% | ||
| Q1 24 | — | 32.7% |
| Q4 25 | 50.6% | 17.0% | ||
| Q3 25 | -11.4% | 13.9% | ||
| Q2 25 | 8.6% | 7.8% | ||
| Q1 25 | -34.0% | 15.5% | ||
| Q4 24 | -6.4% | 20.0% | ||
| Q3 24 | -31.0% | 15.6% | ||
| Q2 24 | 3.5% | 10.2% | ||
| Q1 24 | 52.5% | 7.3% |
| Q4 25 | — | 14.7% | ||
| Q3 25 | -35.9% | 15.3% | ||
| Q2 25 | -15.4% | 11.3% | ||
| Q1 25 | -62.2% | 12.2% | ||
| Q4 24 | — | 11.6% | ||
| Q3 24 | -57.2% | 14.5% | ||
| Q2 24 | -83.9% | 10.4% | ||
| Q1 24 | 44.3% | 10.3% |
| Q4 25 | $0.32 | — | ||
| Q3 25 | $-0.16 | — | ||
| Q2 25 | $-0.06 | — | ||
| Q1 25 | $-0.21 | — | ||
| Q4 24 | $-0.14 | — | ||
| Q3 24 | $-0.15 | — | ||
| Q2 24 | $-0.33 | — | ||
| Q1 24 | $0.34 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $176.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $941.0M |
| Total Assets | $465.9M | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $176.6M | ||
| Q3 25 | $92.4M | $119.8M | ||
| Q2 25 | $86.1M | $170.5M | ||
| Q1 25 | $114.6M | $176.6M | ||
| Q4 24 | $144.8M | $194.6M | ||
| Q3 24 | $144.7M | $163.2M | ||
| Q2 24 | $189.3M | $131.2M | ||
| Q1 24 | $226.6M | $159.4M |
| Q4 25 | $-302.0M | $941.0M | ||
| Q3 25 | $-451.4M | $918.9M | ||
| Q2 25 | $-433.5M | $893.1M | ||
| Q1 25 | $-426.2M | $879.4M | ||
| Q4 24 | $-388.7M | $870.7M | ||
| Q3 24 | $-370.2M | $870.2M | ||
| Q2 24 | $-344.2M | $841.4M | ||
| Q1 24 | $-294.3M | $834.4M |
| Q4 25 | $465.9M | $1.3B | ||
| Q3 25 | $364.0M | $1.2B | ||
| Q2 25 | $347.1M | $1.2B | ||
| Q1 25 | $324.0M | $1.1B | ||
| Q4 24 | $343.8M | $1.1B | ||
| Q3 24 | $314.1M | $1.1B | ||
| Q2 24 | $352.3M | $1.1B | ||
| Q1 24 | $373.1M | $1.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $73.3M |
| Free Cash FlowOCF − Capex | — | $61.0M |
| FCF MarginFCF / Revenue | — | 31.1% |
| Capex IntensityCapex / Revenue | 0.0% | 6.3% |
| Cash ConversionOCF / Net Profit | — | 2.55× |
| TTM Free Cash FlowTrailing 4 quarters | — | $96.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $73.3M | ||
| Q3 25 | $-4.3M | $62.2M | ||
| Q2 25 | $-31.4M | $-8.5M | ||
| Q1 25 | $-22.6M | $3.6M | ||
| Q4 24 | $-35.0M | $68.8M | ||
| Q3 24 | $-35.3M | $61.3M | ||
| Q2 24 | $-7.2M | $-12.6M | ||
| Q1 24 | $53.8M | $21.4M |
| Q4 25 | — | $61.0M | ||
| Q3 25 | — | $50.7M | ||
| Q2 25 | — | $-16.0M | ||
| Q1 25 | — | $750.0K | ||
| Q4 24 | — | $64.7M | ||
| Q3 24 | $-35.5M | $55.8M | ||
| Q2 24 | $-7.3M | $-16.6M | ||
| Q1 24 | $53.8M | $16.9M |
| Q4 25 | — | 31.1% | ||
| Q3 25 | — | 21.8% | ||
| Q2 25 | — | -10.3% | ||
| Q1 25 | — | 0.5% | ||
| Q4 24 | — | 33.5% | ||
| Q3 24 | -68.7% | 24.7% | ||
| Q2 24 | -9.9% | -11.0% | ||
| Q1 24 | 39.0% | 11.0% |
| Q4 25 | 0.0% | 6.3% | ||
| Q3 25 | 0.0% | 5.0% | ||
| Q2 25 | 0.0% | 4.8% | ||
| Q1 25 | 0.0% | 1.9% | ||
| Q4 24 | 0.0% | 2.1% | ||
| Q3 24 | 0.3% | 2.4% | ||
| Q2 24 | 0.1% | 2.6% | ||
| Q1 24 | 0.1% | 2.9% |
| Q4 25 | — | 2.55× | ||
| Q3 25 | — | 1.74× | ||
| Q2 25 | — | -0.49× | ||
| Q1 25 | — | 0.20× | ||
| Q4 24 | — | 3.06× | ||
| Q3 24 | — | 1.87× | ||
| Q2 24 | — | -0.81× | ||
| Q1 24 | 0.88× | 1.35× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
TR
| Products | $194.3M | 99% |
| Rental And Royalty | $1.9M | 1% |
